Epicrispr Biotechnologies has raised $90 million in a Series C round led by Octagon Capital and Janus Henderson Investors, with participation from Sanofi Ventures and several other healthcare investors.
The financing follows early clinical data from its Phase 1/2 trial of EPI-321, an epigenetic editing therapy for facioscapulohumeral muscular dystrophy (FSHD), showing increased lean muscle mass and biomarker changes consistent with suppression of the pathogenic DUX4 gene.
EPI-321 uses CRISPR-based epigenetic editing delivered via a single intravenous adeno‑associated virus (AAV) vector to durably silence DUX4 expression without cutting or permanently altering DNA, positioning it as a potential one‑time, disease‑modifying treatment for FSHD.
The company plans to use the $90 million to advance EPI-321 into pivotal (registrational) studies while expanding its pipeline of programmable epigenetic medicines for other indications.
Sources:
Epicrispr bags $90M to rewrite treatment of rare muscle ...
Epicrispr lands $90M to advance epigenetic editing drug ...
Epicrispr raises $90m Series C to advance FSHD therapy
Epicrispr Biotechnologies | 14 comments
Epicrispr Biotechnologies Named to Fast Company's Annual List of ...
Epicrispr Bio CEO Amber Salzman raises $90M to fight FSHD
Epicrispr raises $90M to rewrite treatment of rare muscle disease
Epicrispr Reports Early Clinical Activity and Favorable Safety Profile ...